Clinical trials: Advanced Gastrointestinal Stromal Tumor
Unresectable Gastrointestinal Stromal Tumor (GIST), Locally Advanced Gastrointestinal Stromal Tumor (GIST)
A Prospective, Randomized, Multicenter, Comparative Study of the Efficacy of Imatinib Resumption Combined With Atezolizumab Versus Imatinib Resumption Alone in Patients With Unresectable Advanced Gastrointestinal Stromal Tumors (GIST) After Failure of Standard Treatments
This trial is a prospective, randomized (1:1 ratio), multicenter, comparative and phase II study, conducted in patients with unresectable advanced gastrointestinal stromal tumors (GIST) after failure of imatinib (disease…
- Conditions
- Unresectable Gastrointestinal Stromal Tumor (GIST), Locally Advanced Gastrointestinal Stromal Tumor (GIST), Metastatic Gastrointestinal Stromal Tumor
- Trial name
- ATEZOGIST (NCT05152472)
- Testing
- Atezolizumab 1200 mg, Imatinib 400 MG
- Where
- 13 sites in France
- Volunteers
- 58 people
- Sponsor
- Centre Leon Berard
Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
This is a study to evaluate the efficacy and safety of belzutifan monotherapy in participants with advanced pheochromocytoma/paraganglioma (PPGL), pancreatic neuroendocrine tumor (pNET), von Hippel-Lindau (VHL) disease-associated…
- Conditions
- Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor, Von Hippel-Lindau Disease, Advanced Gastrointestinal Stromal Tumor
- Trial name
- NCT04924075
- Testing
- Belzutifan
- Where
- 84 sites in United States, Australia and 20 more
- Volunteers
- 355 people
- Sponsor
- Merck Sharp & Dohme LLC
Locally Advanced Gastrointestinal Stromal Tumor, Metastatic Gastrointestinal Stromal Tumor
Autologous Tumor Infiltrating Lymphocytes With Interleukin-2 for the Treatment of Locally Advanced, Recurrent or Metastatic Gastrointestinal Stromal Tumors
This phase II trial tests the effect of autologous tumor infiltrating lymphocytes (TILs) in combination with interleukin-2 (aldesleukin) in treating patients with gastrointestinal stromal tumors (GIST) that has spread to nearby…
- Conditions
- Locally Advanced Gastrointestinal Stromal Tumor, Metastatic Gastrointestinal Stromal Tumor, Recurrent Gastrointestinal Stromal Tumor, Refractory Malignant Gastrointestinal Stromal Tumor
- Trial name
- NCT07647068
- Testing
- Aldesleukin, Biospecimen Collection, Chest Radiography
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- Joal Beane
Advanced Solid Tumors, HER2 Mutation
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Researchers are looking for a better way to treat people who have solid tumors with HER2-activating mutations. Before a treatment can be approved for people to take, researchers do clinical trials to better understand its safety…
- Trial name
- panSOHO (NCT06760819)
- Testing
- BAY2927088
- Where
- 54 sites in United States, Australia and 9 more
- Volunteers
- 111 people
- Sponsor
- Bayer
Locally Advanced Gastrointestinal Stromal Tumor, Locally Advanced Sarcoma
Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST)
This phase II trial studies the effect of rogaratinib in treating patients with sarcoma with a change in a group of proteins called fibroblast growth factor receptors (FGFRs) or SDH-deficient gastrointestinal stromal tumor…
- Conditions
- Locally Advanced Gastrointestinal Stromal Tumor, Locally Advanced Sarcoma, Metastatic Gastrointestinal Stromal Tumor, Metastatic Sarcoma
- Trial name
- NCT04595747
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 18 sites in United States
- Volunteers
- 48 people
- Sponsor
- National Cancer Institute (NCI)
Advanced EGFR Mutant Non Small Cell LungCancer (NSCLC), KRAS G12-mutant NSCLC
Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors
The purpose of this first in human (FIH) trial was to characterize the safety and tolerability of the SHP2 inhibitor TNO155 alone and in combination with EGF816 (nazartinib) and identify a recommended dose for future studies in…
- Conditions
- Advanced EGFR Mutant Non Small Cell LungCancer (NSCLC), KRAS G12-mutant NSCLC, Esophageal Squamous Cell Cancer (SCC), Head/Neck SCC
- Trial name
- NCT03114319
- Testing
- TNO155, TNO155 in combination with EGF816 (nazartinib)
- Where
- 18 sites in United States, Canada and 7 more
- Volunteers
- 227 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Gastrointestinal Stromal Tumors, Metastatic Cancer
(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
This is a Phase 3, open-label, international, multicenter study of CGT9486 in combination with sunitinib. This is a multi-part study that will enroll approximately 482 patients.
- Trial name
- NCT05208047
- Testing
- CGT9486, Sunitinib, Midazolam
- Where
- 126 sites in United States, Argentina and 20 more
- Volunteers
- 482 people
- Sponsor
- Cogent Biosciences, Inc.
GIST - Gastrointestinal Stromal Tumor, Advanced
Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
NB003-04 is a phase II/III, multicenter, open-label clinical study designed to evaluate the efficacy, safety, and pharmacokinetic (PK) profile of NB003 in patients with gastrointestinal stromal tumors aged 18 years and above (or…
- Trial name
- GISTAR-1 (NCT07379047)
- Testing
- NB003, regorafenib
- Where
- 32 sites in China, South Korea
- Volunteers
- 255 people
- Sponsor
- Ningbo Newbay Technology Development Co., Ltd
Advanced Solid Tumours, Squamous Cell Carcinoma of Head and Neck
A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer
This clinical trial is looking at UCB4594. This is the first time the drug is being tested in humans. UCB4594 is a type of drug called a monoclonal antibody.
- Conditions
- Advanced Solid Tumours, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms
- Trial name
- NCT06380816
- Testing
- UCB4594
- Where
- 4 sites in United Kingdom
- Volunteers
- 167 people
- Sponsor
- Cancer Research UK
Advanced Gastrointestinal Stromal Tumors
Efficacy and Safety of PD-0332991 in Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib
The treatment of advanced GIST patients is based on imatinib followed with sunitinib in case of resistance/intolerance. However, the median progression-free survival (PFS) on sunitinib is frequently short, and after failure with…
- Trial name
- CYCLIGIST (NCT01907607)
- Testing
- PD 0332991
- Where
- 9 sites in France
- Volunteers
- 29 people
- Sponsor
- Institut Bergonié
Advanced Gastrointestinal Stromal Tumor
An Observational Study to Learn More About Treatment With Regorafenib in People With Advanced Gastrointestinal Stromal Tumors in the United States
This is an observational study in which data already collected from people with advanced gastrointestinal stromal tumors are studied.
- Trial name
- NCT06321055
- Testing
- Regorafenib (Stivarga, BAY73-4506)
- Where
- United States
- Volunteers
- 136 people
- Sponsor
- Bayer
Gastrointestinal Stromal Tumors, GIST
A Drug-drug Interaction Study of Avapritinib and Midazolam
The purpose of this study is to investigate the effect of multiple dosing of avapritinib on the pharmacokinetics (PK) of midazolam in adult patients with metastatic or unresectable gastrointestinal stromal tumors (GIST)…
- Conditions
- Gastrointestinal Stromal Tumors, GIST, Non-resectable Advanced Solid Tumors, Recurrent or Unresectable Central Nervous System (CNS) Tumors
- Trial name
- NCT04908176
- Testing
- Avapritinib, midazolam
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- Blueprint Medicines Corporation
Advanced Malignant Solid Neoplasm, C-KIT Tyrosine Kinase Protein Overexpression
Ipilimumab and Imatinib Mesylate in Advanced Cancer
This phase I trial studies the side effects and best dose of ipilimumab and imatinib mesylate in treating patients with solid tumors that have spread to other places in the body or cannot be removed by surgery.
- Conditions
- Advanced Malignant Solid Neoplasm, C-KIT Tyrosine Kinase Protein Overexpression, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Gastrointestinal Stromal Tumor
- Trial name
- NCT01738139
- Testing
- Imatinib Mesylate, Ipilimumab
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- M.D. Anderson Cancer Center
Gastrointestinal Stromal Tumors, Advanced Systemic Mastocytosis
A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies
This is a Phase 1, open-label, first-in-human (FIH) dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of DCC-2618, administered…
- Conditions
- Gastrointestinal Stromal Tumors, Advanced Systemic Mastocytosis, Advanced Cancers
- Trial name
- NCT02571036
- Testing
- DCC-2618
- Where
- 26 sites in United States, Canada and 4 more
- Volunteers
- 282 people
- Sponsor
- Deciphera Pharmaceuticals, LLC
Locally Advanced Bone Sarcoma, Locally Advanced Dedifferentiated Liposarcoma
Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery
This randomized phase II trial studies how well nivolumab with or without ipilimumab works in treating patients with sarcoma that has spread from the primary site to other parts of the body (metastatic) or cannot be removed by…
- Conditions
- Locally Advanced Bone Sarcoma, Locally Advanced Dedifferentiated Liposarcoma, Locally Advanced Gastrointestinal Stromal Tumor, Locally Advanced Soft Tissue Sarcoma
- Trial name
- NCT02500797
- Testing
- Ipilimumab, Laboratory Biomarker Analysis, Nivolumab
- Where
- 651 sites in United States
- Volunteers
- 164 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Gastrointestinal Stromal Tumor (GIST), C-KIT Mutation
Efficiency of Imatinib Treatment After 10 Years of Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) (Gist-Ten)
This is a 2 arms study concerning patients under imatinib treatment for at least 10 years of treatment with locally advanced/metastatic GIST. In the first arm, patients will discontinue Imatinib treatment.
- Conditions
- Metastatic Gastrointestinal Stromal Tumor (GIST), C-KIT Mutation, Advanced Gastrointestinal Stromal Tumor (GIST)
- Trial name
- NCT05009927
- Testing
- Imatinib tablets
- Where
- 13 sites in France
- Volunteers
- 50 people
- Sponsor
- Centre Leon Berard
Advanced Gastrointestinal Stromal Tumor (GIST)
BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)
The goal of a phase Ib clinical trial is to find the doses of drugs that are safe. Although BGJ398 has been given to patients safely on its own, it has never been given together with imatinib mesylate.
- Trial name
- NCT02257541
- Testing
- BGJ398, Imatinib Mesylate
- Where
- 7 sites in United States
- Volunteers
- 16 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Metastatic Breast Cancer, Advanced Breast Cancer
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
This is a study using sunitinib for patients ending treatment on a previous sunitinib malate protocol to continue to receive sunitinib.
- Conditions
- Metastatic Breast Cancer, Advanced Breast Cancer, Metastatic Castration Resistant Prostate Cancer, Metastatic Renal Cell Cancer
- Trial name
- NCT00428220
- Testing
- sunitinib
- Where
- 113 sites in United States, Argentina and 15 more
- Volunteers
- 223 people
- Sponsor
- Pfizer
Colorectal Cancer Metastatic, Advanced Non-Small Cell Lung Carcinoma
The Oncopanel Pilot (TOP) Study
The BCCA Oncopanel is a clinical assay being developed to determine genotype status of a prospectively defined set of genes. The purpose of this pilot study is to assess the feasibility and effect on clinical-decision-making of…
- Conditions
- Colorectal Cancer Metastatic, Advanced Non-Small Cell Lung Carcinoma, Advanced Melanoma, Gastrointestinal Stromal Tumors
- Trial name
- NCT02171286
- Where
- 5 sites in Canada
- Volunteers
- 432 people
- Sponsor
- British Columbia Cancer Agency
Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer
This phase I trial is studying the side effects and best dose of erlotinib hydrochloride when given together with cetuximab and to see how well they work in treating patients with advanced gastrointestinal cancer, head and neck…
- Conditions
- Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix
- Trial name
- NCT00397384
- Testing
- cetuximab, erlotinib hydrochloride, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- National Cancer Institute (NCI)